# Rivastigmine

## Exelon patch 5

| 藥物代碼 | EEXEP |
| :--- | :--- |
| 適應症 | Mild to moderate Alzheimer's disease. |
| 副作用 | More frequent: diarrhea; weight loss; Iindigestion; loss of strength ; nausea; vomiting; loss of appetite; abdominal pain; confusion; constipation; depression; dizziness; fatigue ; headache; insomniaLess frequent: high blood pressure; fainting; general feeling of discomfort or illness; increased sweating; runny nose.Rare: aggression; seizures; trembling and shaking of hands and fingers; trouble in urinating |
| 禁忌 | hypersensitivity to rivastigmine, other carbamate derivatives or any other components of the product. |
| 藥物保存方式 | 室溫 \(&lt; 30℃\) |
| 用法用量 | Mild-to-moderate Alzheimer’s dementia: 1.Initial, one patch QD, topically 2.Conversion from oral therapy: If oral daily dose &lt;6 mg, switch to 4.6 mg/24 hours patch. Apply patch on the next day following last oral dose. \* if oral daily dose 6-12 mg, switch to 9.5 mg/24 hours patch\(patch 10\).但目前國內沒有patch 10劑型. Dosage adjustment in renal impairment : No data, but oral form is not required. Dosage adjustment in hepatic impairment : No data, but oral form is not required. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | EXT |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Rivast 2mg/mL 120mL solution

| 藥物代碼 | LRIV |
| :--- | :--- |
| 適應症 | Alzheimer's disease - Dementia \(Mild to Moderate\). Dementia \(Mild to Moderate\) - Parkinson's disease |
| 副作用 | CommonEndocrine metabolic: Weight loss \(26%, female; 18%, male \)Gastrointestinal: Abdominal pain \(13% \), Diarrhea \(7% to 19% \), Indigestion \(9% \), Loss of appetite \(6% to 17% \), Nausea \(29% to 47% \), Vomiting \(13% to 31% \)Neurologic: Asthenia \(4% to 6% \), Dizziness \(6% to 21% \), Headache \(4% to 17% \), Tremor \(4% to 23% \)SeriousCardiovascular: Atrial fibrillation \(1% or more \), Atrioventricular block \(0.1% to 1% \), Myocardial infarction \(1% or more \), Peripheral ischemia \(0.1% to 1% \), Sick sinus syndrome \(0.1% to 1% \)Endocrine metabolic: Hypokalemia \(1% or more \), Hyponatremia \(0.1% to 1% \)Gastrointestinal: Gastrointestinal hemorrhage \(0.1% to 1% \), Hematemesis \(0.1% to 1% \), Melena \(0.1% to 1% \), Pancreatitis \(0.1% to 1% \), Rectal hemorrhage \(0.1% to 1% \), Rupture of esophagusHepatic: Gamma-glutamyl transferase raised \(0.1% to 1% \), Hepatitis, Liver function tests abnormal \(0.1% to 1% \)Neurologic: Cerebrovascular accident, Intracranial hemorrhage \(0.1% to 1% \), Seizure \(1% or more \), Transient ischemic attack \(1% or more \)Ophthalmic: Glaucoma \(0.1% to 1% \)Psychiatric: Suicidal behaviorRenal: Acute renal failure \(0.1% to 1% \)Respiratory: Bronchospasm \(0.1% to 1% \) |
| 禁忌 | Hypersensitivity to rivastigmine, carbamate derivatives, or other components of the product. |
| 藥物保存方式 | 攝氏25度以下 |
| 用法用量 | Initial, 1.5 mg orally twice daily for 2 weeks. Titration, if well tolerated, increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks; Maximum 12 mg/day. If intolerable adverse effects \(eg, nausea, vomiting, abdominal pain, loss of appetite\), interrupt treatment for several doses and restart at same or lower dose |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | \[仿單\]在動物研究上，Rivastigmine 不會導致畸胎\(teratogenic\)， 然而 Rivastigmine 在懷孕婦女身上的安全性尚未建立， 因此，對於懷孕婦女只有在治療利益大於對胎兒危險性下才能給藥。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | \[仿單\]Rivastigmine 會不會被分泌至人類的乳汁中，並不清楚，因此病患服用 Rivastigmine 時不可以哺乳。 |
| 注射劑給藥建議途徑 | PC, WM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Exelon 3mg

| 藥物代碼 | OEXE |
| :--- | :--- |
| 適應症 | Mild to moderately severe dementia of the Alzheimer type. |
| 副作用 | Nausea, vomiting, diarrhea, abdominal pain, loss of appetite, dyspepsia, dizziness, headache.Gastrointestinal: Diarrhea \(6% \), Nausea \(7% \), Vomiting \(6% \) |
| 禁忌 | Serious hypersensitivity to other carbamate derivatives. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Initially 1.5 mg bid. And increase to 3 mg bid after a min of 2 wk of treatment, subsequently to 4.5 mg bid, up to a max of 6 mg bid. Maintenance: 6-12 mg daily. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

